ITM Launches Lumara Bio to Advance Radiopharmaceutical Oncology Pipeline
Garching/Munich, Germany and Princeton, New Jersey – July 27, 2026 ITM Isotope Technologies Munich SE (ITM) has launched Lumara...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Garching/Munich, Germany and Princeton, New Jersey – July 27, 2026 ITM Isotope Technologies Munich SE (ITM) has launched Lumara...
LOS ANGELES, California, June 1, 2026 ITM Isotope Technologies Munich SE announced new findings from its Phase 3 COMPETE...
February 25, 2026 – Garching / Munich, Germany ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotechnology company, has...
